183 related articles for article (PubMed ID: 34382013)
1. Chemical-genetic CRISPR-Cas9 screens in human cells using a pathway-specific library.
Hundley FV; Toczyski DP
STAR Protoc; 2021 Sep; 2(3):100685. PubMed ID: 34382013
[TBL] [Abstract][Full Text] [Related]
2. Optimized protocol for gene editing in adipocytes using CRISPR-Cas9 technology.
Qiu Y; Ding Q
STAR Protoc; 2021 Mar; 2(1):100307. PubMed ID: 33554142
[TBL] [Abstract][Full Text] [Related]
3. Pooled CRISPR Screens in Drosophila Cells.
Viswanatha R; Brathwaite R; Hu Y; Li Z; Rodiger J; Merckaert P; Chung V; Mohr SE; Perrimon N
Curr Protoc Mol Biol; 2019 Dec; 129(1):e111. PubMed ID: 31763777
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide CRISPR-Cas9 screening in mammalian cells.
Yu JSL; Yusa K
Methods; 2019 Jul; 164-165():29-35. PubMed ID: 31034882
[TBL] [Abstract][Full Text] [Related]
5. SliceIt: A genome-wide resource and visualization tool to design CRISPR/Cas9 screens for editing protein-RNA interaction sites in the human genome.
Vemuri S; Srivastava R; Mir Q; Hashemikhabir S; Dong XC; Janga SC
Methods; 2020 Jun; 178():104-113. PubMed ID: 31494246
[TBL] [Abstract][Full Text] [Related]
6. Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens.
Miles LA; Garippa RJ; Poirier JT
FEBS J; 2016 Sep; 283(17):3170-80. PubMed ID: 27250066
[TBL] [Abstract][Full Text] [Related]
7. CRISPR deactivation in mammalian cells using photocleavable guide RNAs.
Zou RS; Liu Y; Ha T
STAR Protoc; 2021 Dec; 2(4):100909. PubMed ID: 34746867
[TBL] [Abstract][Full Text] [Related]
8. Protocol for the saturation and multiplexing of genetic variants using CRISPR-Cas9.
Sahu S; Sullivan T; Southon E; Caylor D; Geh J; Sharan SK
STAR Protoc; 2023 Dec; 4(4):102702. PubMed ID: 37948185
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Based Gene Dropout Screens.
Wu K; Malek SN
Methods Mol Biol; 2019; 1881():185-200. PubMed ID: 30350207
[TBL] [Abstract][Full Text] [Related]
10. Protocol for in vivo CRISPR screening using selective CRISPR antigen removal lentiviral vectors.
Lane-Reticker SK; Kessler EA; Muscato AJ; Kim SY; Doench JG; Yates KB; Manguso RT; Dubrot J
STAR Protoc; 2023 Mar; 4(1):102082. PubMed ID: 36861834
[TBL] [Abstract][Full Text] [Related]
11. Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing.
Klann TS; Crawford GE; Reddy TE; Gersbach CA
Methods Mol Biol; 2018; 1767():447-480. PubMed ID: 29524151
[TBL] [Abstract][Full Text] [Related]
12. Generating mutant
Li HH; Li JC; Su MP; Liu KL; Chen CH
STAR Protoc; 2021 Jun; 2(2):100432. PubMed ID: 33899015
[TBL] [Abstract][Full Text] [Related]
13. Identification of Drug Resistance Mechanisms Using Genome-Wide CRISPR-Cas9 Screens.
MacLeod G; Rajakulendran N; Angers S
Methods Mol Biol; 2022; 2535():141-156. PubMed ID: 35867229
[TBL] [Abstract][Full Text] [Related]
14. Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing.
Zhou L; Li R; Zhang R; Peng R; Chen K; Gao P; Zhang J; Zhang R; Li J
J Clin Lab Anal; 2020 Jul; 34(7):e23256. PubMed ID: 32118319
[TBL] [Abstract][Full Text] [Related]
15. Extensible combinatorial CRISPR screening in mammalian cells.
Zhou P; Wan YK; Chan BKC; Choi GCG; Wong ASL
STAR Protoc; 2021 Mar; 2(1):100255. PubMed ID: 33490975
[TBL] [Abstract][Full Text] [Related]
16. Heritable CRISPR-Cas9 editing of plant genomes using RNA virus vectors.
Uranga M; Aragonés V; Daròs JA; Pasin F
STAR Protoc; 2023 Mar; 4(1):102091. PubMed ID: 36853698
[TBL] [Abstract][Full Text] [Related]
17. Optimized CRISPR/Cas9-mediated single nucleotide mutation in adherent cancer cell lines.
Gao P; Dong X; Wang Y; Wei GH
STAR Protoc; 2021 Jun; 2(2):100419. PubMed ID: 33870225
[TBL] [Abstract][Full Text] [Related]
18. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
[TBL] [Abstract][Full Text] [Related]
19. High-throughput genetic screens using CRISPR-Cas9 system.
Kweon J; Kim Y
Arch Pharm Res; 2018 Sep; 41(9):875-884. PubMed ID: 29637495
[TBL] [Abstract][Full Text] [Related]
20. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
